Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
Recent Posts
- New Study Explores Nalmefene and Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Clinical Opioid Induced Respiratory Depression Model
- Study Examining Use of Nalmefene HCI Injection for Opioid Overdose Reversal in Emergency Departments Concludes Observational Period
- FDA Approves Zurnai™ (nalmefene injection) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose Induced by Natural or Synthetic Opioids in Adults and Pediatric Patients 12 Years and Older
- Purdue Pharma L.P. Enters Agreement to Provide Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
- FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose
Archives
- October 2024
- September 2024
- August 2024
- May 2024
- April 2024
- March 2024
- December 2023
- August 2023
- May 2023
- March 2023
- January 2023
- November 2022
- June 2022
- March 2022
- February 2022
- December 2021
- September 2021
- July 2021
- June 2021
- March 2021
- October 2020
- August 2020
- June 2020
- March 2020
- February 2020
- September 2019
- August 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- October 2018
- September 2018
- August 2018
- February 2018
- January 2018